ARA290 belongs to a research programme built around mimicking a surface feature of erythropoietin. It is not simply a smaller vial of that hormone. The literature also uses cibinetide and pyroglutamate helix B surface peptide terminology. Following those names carefully helps connect molecular design to particular studies without turning a mechanistic description into a general nerve-repair claim.
Follow the surface design rather than a continuous fragment
Brines and colleagues’ 2008 design paper constructed an 11-residue peptide from spatially adjacent residues on erythropoietin’s exposed helix B surface. Those residues are not a continuous segment of the parent’s primary sequence. The paper distinguishes HBSP from its N-terminal pyroglutamate form, pHBSP.Brines and colleagues — Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin (opens in a new tab)
This is why surface mimic is more precise than saying that ARA290 is simply cut from erythropoietin. A three-dimensional design relationship does not require a continuous sequence match.
The supplied ARA290 report names cibinetide and prints pGlu-EQLERALNSS. The pGlu group is part of the molecular description, not an optional spelling convention.Supplied ARA290 10 mg report (opens in a new tab)
| Term | Role |
|---|---|
| ARA290 / ARA 290 | Development name used in research |
| Cibinetide | Name on the supplied report and later trial |
| pHBSP | Pyroglutamate helix B surface peptide description |
A search should include these variants, then verify the test material in each paper. A result for full erythropoietin or another surface-derived peptide should not enter as a direct ARA290 result.
Keep the design objective separate from a universal effect
The original design work reported tissue-protective observations in experimental models while separating those peptides from erythropoietin’s red-cell-stimulating activity. This established a preclinical research rationale for the surface-mimetic approach.Brines and colleagues — Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin (opens in a new tab)
Nonerythropoietic describes the absence of that particular activity in the tested systems. It does not mean that every other biological effect or potential adverse outcome has been excluded.
Similarly, the phrase innate repair receptor summarises a proposed biological target within this programme. The practical evidence question remains which preparation changed which measured outcome, in which model.
This distinction matters when a broad tissue-protection description appears beside a specific disease. The design rationale may motivate that experiment, but it cannot replace its comparison group or results.
Read the sarcoidosis trial endpoint by endpoint
Culver and colleagues’ 2017 phase 2b trial randomised 64 participants with sarcoidosis-associated small nerve fibre loss and neuropathic pain. Its primary endpoint was change in corneal nerve fibre area after 28 days.Culver and colleagues — Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (opens in a new tab)
The intermediate exposure group showed a significant placebo-corrected increase in that imaging measure; the lower and higher groups did not meet the same significance threshold. Pain improved in all groups. The reported placebo-corrected pain comparison in participants with moderate-to-severe pain was not statistically significant.Culver and colleagues — Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (opens in a new tab)
These results should not be compressed into a statement that every tested exposure relieved pain or that a larger exposure produced a larger benefit. The imaging result and pain result support different conclusions.
Organise future findings around the remaining questions
For a new ARA290 paper, record whether it tests molecular activity, nerve morphology, symptoms or function. Also retain the disease population: sarcoidosis-associated small fibre loss is a specific context, not a synonym for all nerve injury.
A later study could strengthen the clinical case by providing a suitable comparison, longer follow-up and consistent patient-relevant outcomes. It could also show that an earlier signal does not generalise. Both are useful additions to the evidence map.
The supplied report can help identify the named material, but its analytical results do not measure nerve regeneration. Keeping the chemistry document and the clinical paper in separate roles makes the overall account more accurate and easier to update.
Sources and further detail
- Supplied ARA290 10 mg report (opens in a new tab)
Complete supplied report read for cibinetide naming and pGlu-EQLERALNSS sequence. No report authentication or clinical equivalence claimed.
- Brines and colleagues — Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin (opens in a new tab)
Original 2008 indexed full-text design and sequence passages read. Spatial surface design distinguished from a contiguous primary-sequence fragment.
- Culver and colleagues — Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (opens in a new tab)
Original 2017 abstract and publisher endpoint/results passages read. Imaging result, non-monotonic group pattern and non-significant pain comparison retained; no administration recommendations.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.